Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Venous Leg Ulcers (Crural ulcer)-Pipeline Review, H1 2015

Venous Leg Ulcers (Crural ulcer)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Venous Leg Ulcers (Crural ulcer)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Venous Leg Ulcers (Crural ulcer)-Pipeline Review, H1 2015', provides an overview of the Venous Leg Ulcers (Crural ulcer)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Venous Leg Ulcers (Crural ulcer) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Venous Leg Ulcers (Crural ulcer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Venous Leg Ulcers (Crural ulcer) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Venous Leg Ulcers (Crural ulcer) Overview 7

Therapeutics Development 8

Pipeline Products for Venous Leg Ulcers (Crural ulcer)-Overview 8

Pipeline Products for Venous Leg Ulcers (Crural ulcer)-Comparative Analysis 9

Venous Leg Ulcers (Crural ulcer)-Therapeutics under Development by Companies 10

Venous Leg Ulcers (Crural ulcer)-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Venous Leg Ulcers (Crural ulcer)-Products under Development by Companies 14

Venous Leg Ulcers (Crural ulcer)-Companies Involved in Therapeutics Development 15

Adocia 15

CardioVascular BioTherapeutics, Inc. 16

CoDa Therapeutics, Inc. 17

CytoTools AG 18

FirstString Research, Inc. 19

Intralytix, Inc. 20

MacroCure Ltd. 21

Pergamum AB 22

RegeneRx Biopharmaceuticals, Inc. 23

Smith & Nephew Plc 24

Stratatech Corporation 25

Venous Leg Ulcers (Crural ulcer)-Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

Cathelicidin-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

CL-05-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

CODA-001-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

CureXcell-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

CVBT-141B-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Granexin-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

HP-802247-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

LL-37-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

RGN-137-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

WPP-201-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Venous Leg Ulcers (Crural ulcer)-Recent Pipeline Updates 52

Venous Leg Ulcers (Crural ulcer)-Dormant Projects 59

Venous Leg Ulcers (Crural ulcer)-Discontinued Products 60

Venous Leg Ulcers (Crural ulcer)-Product Development Milestones 61

Featured News & Press Releases 61

Oct 13, 2014: Smith & Nephew announces top-line results of HP802-247 Phase 3 study 61

May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication 61

Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers 62

Sep 11, 2012: Healthpoint Biotherapeutics Initiates Phase III Study Of Investigational Cell-Based Therapy For Venous Leg Ulcers 62

Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet 63

Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers 64

Aug 04, 2011: Healthpoint Biotherapeutics Announces Positive Results From Phase IIb Trial Of HP802-247 In Venous Leg Ulcers 65

Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results 66

Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial 67

Appendix 68

Methodology 68

Coverage 68

Secondary Research 68

Primary Research 68

Expert Panel Validation 68

Contact Us 68

Disclaimer 69

List of Tables

Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2015 8

Number of Products under Development for Venous Leg Ulcers (Crural ulcer)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Venous Leg Ulcers (Crural ulcer)-Pipeline by Adocia, H1 2015 15

Venous Leg Ulcers (Crural ulcer)-Pipeline by CardioVascular BioTherapeutics, Inc., H1 2015 16

Venous Leg Ulcers (Crural ulcer)-Pipeline by CoDa Therapeutics, Inc., H1 2015 17

Venous Leg Ulcers (Crural ulcer)-Pipeline by CytoTools AG, H1 2015 18

Venous Leg Ulcers (Crural ulcer)-Pipeline by FirstString Research, Inc., H1 2015 19

Venous Leg Ulcers (Crural ulcer)-Pipeline by Intralytix, Inc., H1 2015 20

Venous Leg Ulcers (Crural ulcer)-Pipeline by MacroCure Ltd., H1 2015 21

Venous Leg Ulcers (Crural ulcer)-Pipeline by Pergamum AB, H1 2015 22

Venous Leg Ulcers (Crural ulcer)-Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 23

Venous Leg Ulcers (Crural ulcer)-Pipeline by Smith & Nephew Plc, H1 2015 24

Venous Leg Ulcers (Crural ulcer)-Pipeline by Stratatech Corporation, H1 2015 25

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Stage and Target, H1 2015 28

Number of Products by Stage and Mechanism of Action, H1 2015 30

Number of Products by Stage and Route of Administration, H1 2015 32

Number of Products by Stage and Molecule Type, H1 2015 34

Venous Leg Ulcers (Crural ulcer) Therapeutics-Recent Pipeline Updates, H1 2015 52

Venous Leg Ulcers (Crural ulcer)-Dormant Projects, H1 2015 59

Venous Leg Ulcers (Crural ulcer)-Discontinued Products, H1 2015 60

List of Figures

Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2015 8

Number of Products under Development for Venous Leg Ulcers (Crural ulcer)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 12

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Top 10 Targets, H1 2015 27

Number of Products by Stage and Top 10 Targets, H1 2015 27

Number of Products by Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 30

Number of Products by Top 10 Routes of Administration, H1 2015 31

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31

Number of Products by Top 10 Molecule Types, H1 2015 33

Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adocia

CardioVascular BioTherapeutics, Inc.

CoDa Therapeutics, Inc.

CytoTools AG

FirstString Research, Inc.

Intralytix, Inc.

MacroCure Ltd.

Pergamum AB

RegeneRx Biopharmaceuticals, Inc.

Smith & Nephew Plc

Stratatech Corporation

Venous Leg Ulcers (Crural ulcer) Therapeutic Products under Development, Key Players in Venous Leg Ulcers (Crural ulcer) Therapeutics, Venous Leg Ulcers (Crural ulcer) Pipeline Overview, Venous Leg Ulcers (Crural ulcer) Pipeline, Venous Leg Ulcers (Crural ulcer) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com